nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—FGFR1—cleft lip	0.726	1	CbGaD
Sorafenib—Regorafenib—FGFR2—cleft lip	0.00427	0.5	CrCbGaD
Sorafenib—Regorafenib—FGFR1—cleft lip	0.00427	0.5	CrCbGaD
Sorafenib—CSF1R—periosteum—cleft lip	0.00406	0.0823	CbGeAlD
Sorafenib—CDKL2—telencephalon—cleft lip	0.00304	0.0617	CbGeAlD
Sorafenib—CDKL2—head—cleft lip	0.00189	0.0384	CbGeAlD
Sorafenib—MAPK15—head—cleft lip	0.0017	0.0346	CbGeAlD
Sorafenib—MAPK11—telencephalon—cleft lip	0.00162	0.0329	CbGeAlD
Sorafenib—FLT4—embryo—cleft lip	0.00128	0.026	CbGeAlD
Sorafenib—RET—embryo—cleft lip	0.00113	0.023	CbGeAlD
Sorafenib—KIT—mouth—cleft lip	0.00105	0.0213	CbGeAlD
Sorafenib—FGFR1—telencephalon—cleft lip	0.00103	0.0209	CbGeAlD
Sorafenib—MAPK11—head—cleft lip	0.00101	0.0205	CbGeAlD
Sorafenib—FLT1—embryo—cleft lip	0.000997	0.0202	CbGeAlD
Sorafenib—CDK7—head—cleft lip	0.000994	0.0202	CbGeAlD
Sorafenib—RAF1—embryo—cleft lip	0.000991	0.0201	CbGeAlD
Sorafenib—AURKC—head—cleft lip	0.000979	0.0199	CbGeAlD
Sorafenib—MAP3K7—telencephalon—cleft lip	0.000974	0.0198	CbGeAlD
Sorafenib—MKNK2—telencephalon—cleft lip	0.000944	0.0191	CbGeAlD
Sorafenib—PDGFRA—embryo—cleft lip	0.000934	0.019	CbGeAlD
Sorafenib—MKNK1—telencephalon—cleft lip	0.000932	0.0189	CbGeAlD
Sorafenib—EPHA6—head—cleft lip	0.000906	0.0184	CbGeAlD
Sorafenib—ZAK—head—cleft lip	0.000859	0.0174	CbGeAlD
Sorafenib—RALBP1—telencephalon—cleft lip	0.000852	0.0173	CbGeAlD
Sorafenib—KDR—embryo—cleft lip	0.000843	0.0171	CbGeAlD
Sorafenib—MAP3K19—head—cleft lip	0.000824	0.0167	CbGeAlD
Sorafenib—CSF1R—embryo—cleft lip	0.000822	0.0167	CbGeAlD
Sorafenib—FLT1—telencephalon—cleft lip	0.000811	0.0164	CbGeAlD
Sorafenib—RAF1—telencephalon—cleft lip	0.000806	0.0164	CbGeAlD
Sorafenib—EPHB6—telencephalon—cleft lip	0.000801	0.0163	CbGeAlD
Sorafenib—TIE1—head—cleft lip	0.000786	0.0159	CbGeAlD
Sorafenib—PDGFRA—telencephalon—cleft lip	0.00076	0.0154	CbGeAlD
Sorafenib—KIT—embryo—cleft lip	0.000747	0.0152	CbGeAlD
Sorafenib—PDGFRB—embryo—cleft lip	0.000729	0.0148	CbGeAlD
Sorafenib—MAP2K5—telencephalon—cleft lip	0.000685	0.0139	CbGeAlD
Sorafenib—CSF1R—telencephalon—cleft lip	0.000669	0.0136	CbGeAlD
Sorafenib—FLT4—head—cleft lip	0.000649	0.0132	CbGeAlD
Sorafenib—KIT—telencephalon—cleft lip	0.000607	0.0123	CbGeAlD
Sorafenib—PDGFRB—telencephalon—cleft lip	0.000593	0.012	CbGeAlD
Sorafenib—MKNK2—head—cleft lip	0.000588	0.0119	CbGeAlD
Sorafenib—MKNK1—head—cleft lip	0.00058	0.0118	CbGeAlD
Sorafenib—RET—head—cleft lip	0.000573	0.0116	CbGeAlD
Sorafenib—RALBP1—head—cleft lip	0.000531	0.0108	CbGeAlD
Sorafenib—FLT1—head—cleft lip	0.000505	0.0102	CbGeAlD
Sorafenib—RAF1—head—cleft lip	0.000502	0.0102	CbGeAlD
Sorafenib—HTR2C—telencephalon—cleft lip	0.0005	0.0101	CbGeAlD
Sorafenib—EPHB6—head—cleft lip	0.000499	0.0101	CbGeAlD
Sorafenib—STK10—head—cleft lip	0.000478	0.0097	CbGeAlD
Sorafenib—PDGFRA—head—cleft lip	0.000473	0.0096	CbGeAlD
Sorafenib—HTR2B—telencephalon—cleft lip	0.00047	0.00953	CbGeAlD
Sorafenib—KDR—head—cleft lip	0.000427	0.00866	CbGeAlD
Sorafenib—MAP2K5—head—cleft lip	0.000427	0.00866	CbGeAlD
Sorafenib—CSF1R—head—cleft lip	0.000417	0.00845	CbGeAlD
Sorafenib—KIT—head—cleft lip	0.000378	0.00767	CbGeAlD
Sorafenib—PDGFRB—head—cleft lip	0.000369	0.00749	CbGeAlD
Sorafenib—ABCG2—telencephalon—cleft lip	0.000333	0.00676	CbGeAlD
Sorafenib—HTR2C—head—cleft lip	0.000311	0.00632	CbGeAlD
Sorafenib—ABCC4—head—cleft lip	0.000294	0.00597	CbGeAlD
Sorafenib—HTR2B—head—cleft lip	0.000293	0.00594	CbGeAlD
Sorafenib—CYP2D6—telencephalon—cleft lip	0.000229	0.00464	CbGeAlD
Sorafenib—ABCB1—embryo—cleft lip	0.000202	0.0041	CbGeAlD
Sorafenib—CYP2B6—head—cleft lip	0.000192	0.00389	CbGeAlD
Sorafenib—ABCB1—telencephalon—cleft lip	0.000164	0.00334	CbGeAlD
Sorafenib—CYP2D6—head—cleft lip	0.000142	0.00289	CbGeAlD
Sorafenib—ABCB1—head—cleft lip	0.000102	0.00208	CbGeAlD
Sorafenib—CYP2B6—Metabolism—TCN2—cleft lip	1.18e-05	5.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—NOS3—cleft lip	1.18e-05	5.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—FGF2—cleft lip	1.16e-05	5.37e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGF9—cleft lip	1.16e-05	5.36e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGF9—cleft lip	1.16e-05	5.36e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—FGF2—cleft lip	1.16e-05	5.35e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TCN2—cleft lip	1.15e-05	5.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FGFR2—cleft lip	1.15e-05	5.32e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—FGF2—cleft lip	1.15e-05	5.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGF10—cleft lip	1.15e-05	5.31e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FGFR2—cleft lip	1.15e-05	5.31e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—FGFR1—cleft lip	1.15e-05	5.3e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—NOS3—cleft lip	1.14e-05	5.27e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—NOS3—cleft lip	1.13e-05	5.24e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FGFR1—cleft lip	1.13e-05	5.23e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—FGFR1—cleft lip	1.13e-05	5.23e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGF3—cleft lip	1.13e-05	5.22e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGF3—cleft lip	1.12e-05	5.2e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—FGFR2—cleft lip	1.12e-05	5.18e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MTR—cleft lip	1.12e-05	5.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTCH1—cleft lip	1.12e-05	5.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF8—cleft lip	1.11e-05	5.13e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MTR—cleft lip	1.11e-05	5.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGF9—cleft lip	1.1e-05	5.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGF9—cleft lip	1.1e-05	5.07e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—FGFR3—cleft lip	1.08e-05	5.01e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGF10—cleft lip	1.08e-05	5.01e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC19A1—cleft lip	1.08e-05	4.99e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MTHFR—cleft lip	1.08e-05	4.99e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—FGF2—cleft lip	1.08e-05	4.98e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGF10—cleft lip	1.07e-05	4.97e-05	CbGpPWpGaD
Sorafenib—MKNK1—Disease—MYC—cleft lip	1.07e-05	4.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FGFR1—cleft lip	1.07e-05	4.95e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—FGFR3—cleft lip	1.07e-05	4.94e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FGFR3—cleft lip	1.07e-05	4.94e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTCH1—cleft lip	1.07e-05	4.93e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FGFR2—cleft lip	1.06e-05	4.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGF10—cleft lip	1.06e-05	4.91e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FGFR2—cleft lip	1.06e-05	4.9e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC19A1—cleft lip	1.05e-05	4.87e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—FGFR1—cleft lip	1.04e-05	4.83e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF7—cleft lip	1.04e-05	4.8e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPRY2—cleft lip	1.04e-05	4.8e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGFR2—cleft lip	1.04e-05	4.8e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—FGF2—cleft lip	1.03e-05	4.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—FGF2—cleft lip	1.03e-05	4.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FGFR2—cleft lip	1.03e-05	4.78e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MTHFR—cleft lip	1.02e-05	4.73e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—NOS3—cleft lip	1.02e-05	4.72e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MTHFR—cleft lip	1.02e-05	4.72e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FGFR3—cleft lip	1.01e-05	4.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGF3—cleft lip	1.01e-05	4.69e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FGFR3—cleft lip	1.01e-05	4.68e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGFR2—cleft lip	1.01e-05	4.68e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TCN2—cleft lip	1e-05	4.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTCH1—cleft lip	9.96e-06	4.61e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC19A1—cleft lip	9.91e-06	4.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FGFR1—cleft lip	9.88e-06	4.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGF9—cleft lip	9.88e-06	4.57e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—FGFR3—cleft lip	9.86e-06	4.56e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC19A1—cleft lip	9.82e-06	4.55e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGF10—cleft lip	9.77e-06	4.52e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGF10—cleft lip	9.77e-06	4.52e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGFR1—cleft lip	9.67e-06	4.47e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGF3—cleft lip	9.66e-06	4.47e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FGFR1—cleft lip	9.64e-06	4.46e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF8—cleft lip	9.57e-06	4.43e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGFR2—cleft lip	9.55e-06	4.42e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGFR1—cleft lip	9.42e-06	4.36e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGF9—cleft lip	9.42e-06	4.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FGFR3—cleft lip	9.36e-06	4.33e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FGFR3—cleft lip	9.33e-06	4.32e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGF10—cleft lip	9.27e-06	4.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGF10—cleft lip	9.25e-06	4.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGFR2—cleft lip	9.21e-06	4.26e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—MYC—cleft lip	9.21e-06	4.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MTHFR—cleft lip	9.19e-06	4.25e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—FGF2—cleft lip	9.15e-06	4.24e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGFR3—cleft lip	9.14e-06	4.23e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FGFR3—cleft lip	9.11e-06	4.21e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—MYC—cleft lip	9.06e-06	4.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF3—cleft lip	9.03e-06	4.18e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TCN2—cleft lip	8.93e-06	4.13e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGFR3—cleft lip	8.9e-06	4.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGFR1—cleft lip	8.9e-06	4.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF9—cleft lip	8.8e-06	4.07e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TCN2—cleft lip	8.71e-06	4.03e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGFR2—cleft lip	8.69e-06	4.02e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGFR2—cleft lip	8.61e-06	3.99e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTCH1—cleft lip	8.6e-06	3.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGFR1—cleft lip	8.59e-06	3.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGFR2—cleft lip	8.51e-06	3.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGFR3—cleft lip	8.41e-06	3.89e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC19A1—cleft lip	8.4e-06	3.89e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—FGF2—cleft lip	8.37e-06	3.87e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGF10—cleft lip	8.33e-06	3.85e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—NOS3—cleft lip	8.26e-06	3.82e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FGF2—cleft lip	8.25e-06	3.82e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—FGF2—cleft lip	8.25e-06	3.82e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TCN2—cleft lip	8.21e-06	3.8e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTR—cleft lip	8.19e-06	3.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MTHFR—cleft lip	8.19e-06	3.79e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TCN2—cleft lip	8.14e-06	3.77e-05	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—MYC—cleft lip	8.14e-06	3.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGFR3—cleft lip	8.12e-06	3.76e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGFR1—cleft lip	8.1e-06	3.75e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—TYMS—cleft lip	8.07e-06	3.74e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—TYMS—cleft lip	8.07e-06	3.74e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	8.04e-06	3.72e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGFR1—cleft lip	8.03e-06	3.71e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTR—cleft lip	8e-06	3.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGF10—cleft lip	7.94e-06	3.68e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGFR1—cleft lip	7.93e-06	3.67e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGFR2—cleft lip	7.84e-06	3.63e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGFR2—cleft lip	7.84e-06	3.63e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FGF2—cleft lip	7.83e-06	3.62e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FGF2—cleft lip	7.81e-06	3.62e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF3—cleft lip	7.79e-06	3.61e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGFR3—cleft lip	7.66e-06	3.54e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—FGF2—cleft lip	7.62e-06	3.53e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF9—cleft lip	7.6e-06	3.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGFR3—cleft lip	7.59e-06	3.51e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—MYC—cleft lip	7.56e-06	3.5e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NOS3—cleft lip	7.51e-06	3.48e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MYC—cleft lip	7.51e-06	3.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGFR3—cleft lip	7.49e-06	3.47e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGFR2—cleft lip	7.44e-06	3.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF10—cleft lip	7.42e-06	3.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGFR2—cleft lip	7.42e-06	3.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGFR1—cleft lip	7.31e-06	3.38e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGFR1—cleft lip	7.31e-06	3.38e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FGF2—cleft lip	7.23e-06	3.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FGF2—cleft lip	7.21e-06	3.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOS3—cleft lip	7.13e-06	3.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS3—cleft lip	7.11e-06	3.29e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGF2—cleft lip	7.06e-06	3.27e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—MTHFR—cleft lip	7.05e-06	3.26e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—MTHFR—cleft lip	7.05e-06	3.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FGF2—cleft lip	7.04e-06	3.26e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NOS3—cleft lip	6.96e-06	3.22e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TCN2—cleft lip	6.96e-06	3.22e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTR—cleft lip	6.93e-06	3.21e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGFR1—cleft lip	6.92e-06	3.2e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGFR3—cleft lip	6.9e-06	3.2e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGFR3—cleft lip	6.9e-06	3.2e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGF2—cleft lip	6.88e-06	3.18e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—TYMS—cleft lip	6.85e-06	3.17e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—TYMS—cleft lip	6.79e-06	3.14e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NOS3—cleft lip	6.79e-06	3.14e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MYC—cleft lip	6.76e-06	3.13e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGFR2—cleft lip	6.68e-06	3.09e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGFR3—cleft lip	6.55e-06	3.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGFR3—cleft lip	6.54e-06	3.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGF2—cleft lip	6.5e-06	3.01e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC19A1—cleft lip	6.48e-06	3e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF10—cleft lip	6.41e-06	2.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS3—cleft lip	6.41e-06	2.97e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGFR2—cleft lip	6.37e-06	2.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGF2—cleft lip	6.27e-06	2.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGFR1—cleft lip	6.23e-06	2.88e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTR—cleft lip	6.19e-06	2.86e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTR—cleft lip	6.04e-06	2.8e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MTHFR—cleft lip	5.98e-06	2.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGFR2—cleft lip	5.96e-06	2.76e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—MYC—cleft lip	5.95e-06	2.75e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGFR1—cleft lip	5.94e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MTHFR—cleft lip	5.93e-06	2.74e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGF2—cleft lip	5.92e-06	2.74e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGFR3—cleft lip	5.89e-06	2.73e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGF2—cleft lip	5.86e-06	2.71e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NOS3—cleft lip	5.84e-06	2.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGF2—cleft lip	5.79e-06	2.68e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NOS3—cleft lip	5.78e-06	2.68e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS3—cleft lip	5.71e-06	2.64e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTR—cleft lip	5.69e-06	2.63e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTR—cleft lip	5.64e-06	2.61e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGFR3—cleft lip	5.62e-06	2.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGFR1—cleft lip	5.55e-06	2.57e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—cleft lip	5.47e-06	2.53e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TCN2—cleft lip	5.37e-06	2.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGF2—cleft lip	5.34e-06	2.47e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGF2—cleft lip	5.34e-06	2.47e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—cleft lip	5.26e-06	2.44e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—cleft lip	5.26e-06	2.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGFR3—cleft lip	5.25e-06	2.43e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGFR2—cleft lip	5.14e-06	2.38e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGF2—cleft lip	5.06e-06	2.34e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGF2—cleft lip	5.05e-06	2.34e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—TYMS—cleft lip	5.02e-06	2.32e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—cleft lip	4.99e-06	2.31e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—cleft lip	4.98e-06	2.31e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—cleft lip	4.98e-06	2.31e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—cleft lip	4.92e-06	2.28e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—cleft lip	4.92e-06	2.28e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TYMS—cleft lip	4.91e-06	2.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTR—cleft lip	4.82e-06	2.23e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGFR1—cleft lip	4.79e-06	2.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—cleft lip	4.73e-06	2.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—cleft lip	4.72e-06	2.18e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—cleft lip	4.62e-06	2.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGF2—cleft lip	4.55e-06	2.11e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGFR3—cleft lip	4.53e-06	2.1e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—cleft lip	4.5e-06	2.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—cleft lip	4.49e-06	2.08e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—cleft lip	4.39e-06	2.03e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGF2—cleft lip	4.34e-06	2.01e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—cleft lip	4.29e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—cleft lip	4.28e-06	1.98e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TYMS—cleft lip	4.25e-06	1.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—cleft lip	4.25e-06	1.97e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—cleft lip	4.17e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—cleft lip	4.14e-06	1.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF2—cleft lip	4.06e-06	1.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—cleft lip	4e-06	1.85e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—cleft lip	3.87e-06	1.79e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—cleft lip	3.83e-06	1.77e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TYMS—cleft lip	3.79e-06	1.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—cleft lip	3.79e-06	1.75e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTR—cleft lip	3.72e-06	1.72e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—cleft lip	3.71e-06	1.72e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TYMS—cleft lip	3.7e-06	1.71e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF2—cleft lip	3.5e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—cleft lip	3.49e-06	1.61e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—cleft lip	3.49e-06	1.61e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—cleft lip	3.49e-06	1.61e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—cleft lip	3.46e-06	1.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—cleft lip	3.45e-06	1.6e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—cleft lip	3.31e-06	1.53e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—cleft lip	3.31e-06	1.53e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—cleft lip	3.3e-06	1.53e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—cleft lip	3.23e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—cleft lip	3.06e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—cleft lip	3.05e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—cleft lip	3.02e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—cleft lip	2.99e-06	1.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—cleft lip	2.97e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—cleft lip	2.96e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—cleft lip	2.84e-06	1.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—cleft lip	2.65e-06	1.23e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—cleft lip	2.59e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—cleft lip	2.58e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—cleft lip	2.31e-06	1.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—cleft lip	2.29e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—cleft lip	2.28e-06	1.06e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—cleft lip	2.26e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—cleft lip	2.13e-06	9.84e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—cleft lip	2.11e-06	9.75e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—cleft lip	1.99e-06	9.22e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—cleft lip	1.8e-06	8.33e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—cleft lip	1.39e-06	6.43e-06	CbGpPWpGaD
